Review article‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: A comprehensive review
Introduction
Achieving tolerance has been considered the holy grail of transplantation. Autoimmune hepatitis (AIH) appears to be at the opposite end of tolerance in the transplant immunological spectrum [1]. Waldenström gave the first description of AIH, or ‘chronic active hepatitis’ as it was previously known, in 1950; when it's predominance was reported in young women, with a fluctuating course, extreme hypergammaglobulinemia, associated features of arthralgia/myalgia, hepatosplenomegaly, amenorrhea, skin rashes and invariably fatal outcome [2]. After the discovery of the hepatitis C virus (HCV) in 1989, there was uncertainty in the liver disorder that was then known as chronic active hepatitis [3]. In 1992, an international panel of experts (international Autoimmune Hepatitis Group – IAHG) met and developed a scoring system to diagnose AIH as there was no single pathognomonic feature [4]. This scoring system has since been revised and simplified [5], [6]. Progress has been made since the first description of AIH but the underlying mechanism of the development of AIH before or after liver transplantation (LT) is still unknown [7]. The present review will focus on the occurrence of AIH after LT and includes ‘de novo’ as well as ‘recurrent’ AIH.
Section snippets
‘De novo’ autoimmune hepatitis
The term ‘de novo’ AIH (dn-AIH) was first used to describe the development of AIH in pediatric LT recipients whose indications for transplant were non-autoimmune [8]. In the original report, 4% of 180 pediatric recipients whose indication for LT included biliary atresia (n = 4), Alagille syndrome (n = 1), alpha-1antitrypsin deficiency (n = 1) and fulminant liver failure secondary to isoniazid toxicity (n = 1); developed dn-AIH at a median interval of 24 months from LT. No patient had been
‘De novo’ AIH in adults
The first report in adults of the development of AIH after LT in patients not transplanted for AIH, was a year after the original pediatric report. The indication for LT in the two adults was primary biliary cirrhosis (PBC) and both patients responded to reinstitution of steroid therapy [22]. The fact that there was multiple HLA class 1 allele matches between donor and recipient led the authors to speculate that HLA class 1-restricted mechanisms could have a role to play. Other reports [23],
Management
The treatment of recurrent AIH is challenging and is usually empiric. It includes re-starting or intensifying corticosteroid therapy, reinforcing adherence to medical therapy, adding new immunosuppressive agents as substitutes for failed drugs and consideration for re-transplant evaluation for refractory cases. Corticosteroids are the mainstay of treatment for AIH. Their effectiveness may relate to the multiplicity of their actions that include anti-inflammatory and immunosuppression effects.
Conclusion
Autoimmune hepatitis should be considered in the differential diagnosis of graft dysfunction in patients transplanted not only for AIH (recurrent AIH) but also for other liver diseases (dn-AIH). The development of autoimmunity may be silent and manifest only by laboratory changes reflective of graft inflammation or by histological changes noted on surveillance biopsies. The presence of autoantibodies, hypergammaglobulinemia, histological findings of interface hepatitis and the absence of other
References (95)
International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis
J. Hepatol.
(1999)De-novo autoimmune hepatitis after liver transplantation
Lancet
(1998)De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby: a case report
Transpl. Proc.
(2009)A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis
Transpl. Proc.
(2001)A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis
Transpl. Proc.
(2002)Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis
Am. J. Transpl.
(2007)De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution's experience
Transpl. Proc.
(2011)- et al.
Clinical significance of autoantibodies in autoimmune hepatitis
J. Autoimmun.
(2013) - et al.
Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation
Liver Transpl.
(2001) De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis
Transpl. Proc.
(2006)
De novo autoimmune hepatitis following liver transplantation: a case report
Transpl. Proc.
Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?
Dig. Liver Dis.
Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”
Am. J. Transpl.
Autoimmune hepatitis after liver transplantation
Clin. Gastroenterol. Hepatol.
Effects of cyclosporine on transplant tolerance: the role of IL-2
Am. J. Transpl.
Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease
J. Hepatol.
Type 2 autoimmune hepatitis and hepatitis C virus infection
Lancet
Molecular mimicry and autoimmune disease
Cell
Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus
Gastroenterology
Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance
Lancet
Immunosuppression and outcomes of patients transplanted for hepatitis C
J. Hepatol.
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C
Liver Transpl.
Rapamycin successfully treats post-transplant autoimmune hepatitis
Am. J. Transpl.
Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports
Transpl. Proc.
Primary biliary cirrhosis: a 2010 update
J. Hepatol.
Autoimmune hepatitis and PSC connection
Clin. Liver Dis.
Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients
Liver Transpl.
Liver transplantation for autoimmune hepatitis
Hepatology
Recurrent autoimmune hepatitis after orthotopic liver transplantation
Liver Transpl.
Short-term cyclosporine induces a remission of autoimmune hepatitis in children
J. Hepatol.
Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance
Liver Transpl.
Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome
Liver Transpl.
Liver transplantation for autoimmune hepatitis: a long-term pathologic study
Hepatology
Clinical features and pathobiology of ebolavirus infection
J. Autoimmun.
Lyme disease: a rigorous review of diagnostic criteria and treatment
J. Autoimmun.
From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela
J. Autoimmun.
Autoimmune hepatitis
Nat. Rev. Gastroenterol. Hepatol.
Blutproteine und Nahrungseiweiss
Dtsch. Ges. Verdau. Stoffwechs.
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
Science
Meeting report: International Autoimmune Hepatitis Group
Hepatology
Simplified criteria for the diagnosis of autoimmune hepatitis
Hepatology
Autoimmune hepatitis: 50 years of (slow) progress
Hepatology
Autoimmune hepatitis as a late complication of liver transplantation
J. Pediatr. Gastroenterol. Nutr.
De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation
Transplantation
Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine
Transplantation
De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation
Transplantation
Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation
Pediatr. Transpl.
Cited by (71)
Molecular mimicry and autoimmunity in the time of COVID-19
2023, Journal of AutoimmunityTransplantation Pathology
2023, MacSween's Pathology of the Liver, Eighth EditionApproach to the patient with acute severe autoimmune hepatitis
2020, JHEP ReportsRecurrence of Disease After Liver Transplantation
2020, Pediatric Liver TransplantationImmunological and Other Late Complications
2020, Pediatric Liver TransplantationAutoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes
2020, Current Therapeutic Research - Clinical and ExperimentalCitation Excerpt :Despite liver transplantation being an infrequent indication (<10%), owing to the therapeutic advances of immunosuppression,23 the relatively high percentage of patients undergoing liver transplantation in our study may be related to the restricted accessibility to other therapeutic options because of the high cost. However, even with optimal results after liver transplantation, AIH can recur in the allograft in up to 68% of patients after 5 years.24 Thus, we agree with Liberal et al25 that the criteria for prospective studies should focus on these issues and move from expert opinion to evidence-based, personalized care for patients with AIH.